Helix Acquisition Corp. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Helix Acquisition Corp. (“Helix” or the “Company”) (NASDAQ: HLXA) with MoonLake Immunotherapeutics AG. Upon the closing of the transaction, the company will be renamed “MoonLake Immunotherapeutics”, and the combined company’s common stock is expected to be listed on Nasdaq under the ticker symbol MLTX.

The Helix merger investigation concerns whether the Board of Helix has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.